LMAT CEO exercises 2,681 options, holds 1.67M+ shares

Q: What insider transaction did LMAT's CEO report on this Form 4?

The Chairman and CEO of LeMaitre Vascular, Inc. (LMAT) reported exercising a stock option for 2,681 shares of common stock at an exercise price of $41.02 per share on 11/20/2025.

Q: What happened to the LMAT stock option reported in Table II?

A stock option to acquire 2,681 shares of LMAT common stock at $41.02, which was fully vested and exercisable, was exercised on 11/20/2025, leaving 0 derivative securities from that option grant.

Q: What is the nature of the indirect ownership reported for LMAT shares?

The Form 4 states that 21,300 shares are held by the LeMaitre Irrevocable Life Insurance Trust of 2025 for the benefit of the reporting person’s child(ren), and the reporting person disclaims beneficial ownership except for any pecuniary interest.

Q: What roles does the reporting person hold at LeMaitre Vascular (LMAT)?

The reporting person is identified as a Director and an Officer, specifically serving as Chairman and CEO of LeMaitre Vascular, Inc.

Q: Is this LMAT Form 4 filed for a single reporting person or a group?

The filing indicates that it is a Form filed by one reporting person, not a joint or group filing.

LeMaitre Vascular, Inc. (LMAT) Chairman and CEO, who is also a director, reported an insider transaction on 11/20/2025.

Filing Impact

(Moderate)

Filing Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. (LMAT) Chairman and CEO, who is also a director, reported an insider transaction on 11/20/2025. He exercised a stock option to buy 2,681 shares of common stock at an exercise price of $41.02 per share, converting a derivative position into directly owned stock. After this exercise, he directly beneficially owns 1,665,984 shares of LeMaitre Vascular common stock.

In addition, 21,300 shares are held indirectly through the “LeMaitre Irrevocable Life Insurance Trust of 2025” for the benefit of his child or children. He disclaims beneficial ownership of those trust-held shares except to the extent of any pecuniary interest. The option that was exercised covered 2,681 shares, was fully vested and exercisable, and now shows 0 derivative securities remaining from that grant.

Insider Trade Summary

2,681 shares exercised/converted

Exercise 3 txns

Insider LeMaitre George W

Role Chairman and CEO

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	2,681	$0.00	$0.00
Exercise	Common Stock	2,681	$41.02	$110K
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 1,665,984 shares (Direct); Common Stock — 21,300 shares (Indirect, LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025)

Footnotes (3)

F1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.
F2. These shares are held by an irrevocable trust for the benefit of Reporting Person's child(ren). The Reporting Person disclaims ownership of such securities except to the extent of his pecuniary interest therein, if any, and the reporting herein of such securities shall not be construed as an admission of beneficial ownership thereof for the purposes of Section 16 or for any other purpose.
F3. This option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LMAT's CEO report on this Form 4?

The Chairman and CEO of LeMaitre Vascular, Inc. (LMAT) reported exercising a stock option for 2,681 shares of common stock at an exercise price of $41.02 per share on 11/20/2025.

How many LMAT shares does the reporting person own after this transaction?

Following the reported transaction, the reporting person directly beneficially owns 1,665,984 shares of LeMaitre Vascular common stock and has 21,300 shares held indirectly through a trust.

What happened to the LMAT stock option reported in Table II?

A stock option to acquire 2,681 shares of LMAT common stock at $41.02, which was fully vested and exercisable, was exercised on 11/20/2025, leaving 0 derivative securities from that option grant.

What is the nature of the indirect ownership reported for LMAT shares?

The Form 4 states that 21,300 shares are held by the LeMaitre Irrevocable Life Insurance Trust of 2025 for the benefit of the reporting person’s child(ren), and the reporting person disclaims beneficial ownership except for any pecuniary interest.

What roles does the reporting person hold at LeMaitre Vascular (LMAT)?

The reporting person is identified as a Director and an Officer, specifically serving as Chairman and CEO of LeMaitre Vascular, Inc.

Is this LMAT Form 4 filed for a single reporting person or a group?

The filing indicates that it is a Form filed by one reporting person, not a joint or group filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 11/21/2025 - 05:36 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeMaitre George W

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

01803

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chairman and CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	11/20/2025		M		2,681⁽¹⁾	A	$41.02	1,665,984	D
Common Stock								21,300	I	LEMAITRE IRREVOCABLE LIFE INSURANCE TRUST OF 2025⁽²⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$41.02	11/20/2025		M			2,681	12/02/2020⁽³⁾	12/02/2025	Common Stock	2,681	$0	0	D

Explanation of Responses:

1. Represents shares acquired upon exercise of options by the Reporting Person, as reported in Table II.

2. These shares are held by an irrevocable trust for the benefit of Reporting Person's child(ren). The Reporting Person disclaims ownership of such securities except to the extent of his pecuniary interest therein, if any, and the reporting herein of such securities shall not be construed as an admission of beneficial ownership thereof for the purposes of Section 16 or for any other purpose.

3. This option is fully vested and exercisable.

	/s/ Laurie A. Churchill, Attorney-in-fact	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR